KNCV Tuberculosis Foundation is an international non-profit organization dedicated to the fight against tuberculosis (TB), the first deadliest infectious disease in the world. KNCV is an international center of expertise for TB control that promotes effective, efficient, innovative and sustainable tuberculosis control strategies in a national and international context.
We are an organization of passionate TB professionals, including doctors, researchers, training experts, nurses and epidemiologists. We aim to stop the spread of the worldwide epidemic of TB and to prevent the further spread of drug-resistant TB. We operate from a central office in The Hague in the Netherlands, a regional office in Central Asia and country offices worldwide. KNCV raises funds from private, institutional, corporate, and government donors.
Latent tuberculosis (TB) infection (LTBI) is the seed bed for developing TB disease and continued transmission as it’s estimated that close to a quarter of the world’s population has LTBI. The World Health Organization (WHO) policy to give at least six months of isoniazid preventive therapy (IPT) to people living with HIV (PLWHIV) and child contacts has existed since 1993, yet the uptake of IPT in high burden countries remains poor. A short-course regimen of isoniazid and rifapentine weekly for three months (3HP) is now available. 3HP is associated with less toxicity, better adherence and at least similar efficacy to IPT and may be logistically easier for programs to scale up. WHO has included scaling up TB preventive therapy, particularly short-course regimens, in its End TB strategy? implementation of 3HP will meet the same fate as IPT unless existing barriers to its supply, adoption, demand and delivery are removed.
The IMPAACT4TB consortium is led by the Aurum Institute with core partners Clinton Health Access Initiative, Johns Hopkins University (JHU), KNCV Tuberculosis Foundation and the Global Drug Facility. The goal of the IMPAACT4TB project is to reduce TB incidence among PLHIV and child contacts<5 living in low and middle-income countries by contributing to the sustainable scale up of 3HP preventive therapy. The project will utilize the UNITAID grant to start 400,000 people on 3HP and catalyze an increase in supply, demand for and uptake of 3HP in focus countries with the outcome of starting >1 million child contacts and PLWHIV on 3HP. JHU is leading a cluster randomized trial in Malawi called “Choice Architecture Based TB Preventive Therapy Prescribing”. The primary objective of this study is to use a feasible, low-resource strategy to achieve levels of 3HP delivery substantially higher than routine implementation in primary care public clinics. The study protocol received conditional approval from the WHO ERC in January, local IRS approvals are underway. KNCV is leading the implementation process in Ethiopia, Tanzania, Malawi, and Indonesia.
KNCV Tuberculosis Foundation is looking for full time
Research assistants for IMPAACT4TB Project (4 positions)
Duty Station: Mzimba North and Mulanje, Malawi – 2 in each district
Position in the organization
Research Assistants will collect data and lead monitoring and evaluation of Choice architecture based TPT Study activities. He/she will report directly to the Study Coordinator and will maintain close communication and coordination with the IMPAACT4TB Project Manager. The positions are available at the district level with frequent visits to the assigned study sites in the district.
The positions are expected to be filled soon after approval of the protocol by ERB.
Who are we looking for?